Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bayer ( (DE:BAYN) ) just unveiled an update.
Bayer disclosed a managers’ transaction involving CEO and board member William N. Anderson, who, together with his wife via a joint account, purchased Bayer shares on the Xetra exchange. The acquisition, worth about €789,585 at a price of €37.51 per share, was made in connection with the Board of Management members’ commitment to buy Bayer stock, underscoring executive alignment with shareholders under EU market abuse regulations.
The transaction notification, made under Article 19 of the Market Abuse Regulation, reflects ongoing governance and transparency requirements for insider dealings at large listed issuers such as Bayer. Such sizeable insider buying by top management can signal confidence in the company’s outlook to investors and may be closely watched by the market for indications of leadership’s assessment of Bayer’s valuation and strategic trajectory.
The most recent analyst rating on (DE:BAYN) stock is a Buy with a EUR48.00 price target. To see the full list of analyst forecasts on Bayer stock, see the DE:BAYN Stock Forecast page.
More about Bayer
Bayer Aktiengesellschaft is a Germany-based life science company with core businesses in pharmaceuticals, consumer health and crop science. Its shares are listed on multiple regulated markets in Germany, and it targets global healthcare and agricultural markets with a diversified portfolio of patented medicines, over-the-counter products and agricultural solutions.
YTD Price Performance: -1.68%
Average Trading Volume: 3,861,126
Technical Sentiment Signal: Sell
Current Market Cap: €35.75B
See more insights into BAYN stock on TipRanks’ Stock Analysis page.